...
首页> 外文期刊>Journal of chemotherapy >Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.
【24h】

Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.

机译:老年非小细胞肺癌:与年轻患者相比,临床病理,管理和预后特征。

获取原文
获取原文并翻译 | 示例
           

摘要

It is controversial whether non-small cell lung cancer (NSCLC) in the elderly constitutes a distinct clinico-biological entity compared to younger counterparts. As reported data are scant and discordant, we sought to analyze retrospectively the medical records of Hellenic NSCLC patients aged >70 years and compare them with those of age (70-45 years) and younger (<45 years) patients. Records were abstracted from the Hellenic Cooperative Oncology Group (HeCOG) cancer registry database. Presentation, management and outcome data of 417 elderly patients aged > or =70, 1374 age 70-45 years old and 115 patients aged < or =45 years old with histologically confirmed NSCLC managed from 1989 until 2004 were retrieved and compared. Elderly patients differed significantly in terms of presence of symptoms (p<0.001), including thoracic pain (p=0.003), dyspnea (p<0.001), cough (p<0.001) and fatigue (p<0.001), eastern Cooperative Oncology Group performance status (PS) 2-3 (p<0.001), and histological type (more commonly diagnosed with squamous cell carcinoma (p<0.002) and less frequently with adenocarcinoma). Although elderly patients had significantly higher rates of PS 2-3, they had significantly better median time to disease progression (TTP) compared to the younger counterpart (6.4 versus 4.3 months p=0.047). Overall survival (OS) was not significantly different between elderly and young patients (median OS 11.8 versus 11.5 months; p=0.6), but platinum-based chemotherapy and radiotherapy were variables associated favorably with TTP and survival in the elderly. This large retrospective series presents strong evidence that NSCLC constitutes a similar clinicopathologic entity in elderly and young individuals with discretely differing biological behavior and that elderly symptomatic patients should be considered for effective anticancer treatment whenever possible.
机译:与年轻的非小细胞肺癌相比,老年人的非小细胞肺癌(NSCLC)是否构成独特的临床生物学实体存在争议。由于报道的数据很少且不一致,我们试图回顾性分析年龄> 70岁的希腊NSCLC患者的病历,并将其与年龄(70-45岁)和年轻(<45岁)的患者进行比较。记录是从希腊合作肿瘤小组(HeCOG)癌症登记数据库中提取的。检索并比较了1989年至2004年经组织学确认的NSCLC的417例≥70岁的老年患者,1374例70-45岁的115例年龄≥45岁的老年患者的表现,治疗和结果。东部患者在出现症状(p <0.001)方面存在显着差异(p <0.001),包括胸痛(p = 0.003),呼吸困难(p <0.001),咳嗽(p <0.001)和疲劳(p <0.001),东部合作肿瘤小组表现状态(PS)2-3(p <0.001)和组织学类型(较常诊断为鳞状细胞癌(p <0.002),而较不常见于腺癌)。尽管老年患者的PS 2-3发生率明显更高,但与年轻患者相比,他们的疾病进展中位时间(TTP)显着更好(6.4 vs 4.3个月,p = 0.047)。老年患者和青年患者的总生存期(OS)无显着差异(中位生存期11.8个月与11.5个月; p = 0.6),但是铂类化疗和放疗与TTP和老年人生存率相关。大量回顾性研究提供了强有力的证据,表明NSCLC在生物学行为截然不同的老年和年轻个体中构成相似的临床病理实体,并且应尽可能考虑对有症状的老年患者进行有效的抗癌治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号